Type 2 diabetes as a determinant of Parkinson’s disease risk and progression
View ORCID ProfileHarneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce
doi: https://doi.org/10.1101/2020.11.12.20230474
Harneek Chohan
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
MScKonstantin Senkevich
2Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada
3Montreal Neurological Institute, McGill University, Montréal, QC, Canada
MD, PhDRadhika K Patel
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
Jonathan P Bestwick
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
MScBenjamin M Jacobs
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
BM BChSara Bandres Ciga
4Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
PhDZiv Gan-Or
2Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada
3Montreal Neurological Institute, McGill University, Montréal, QC, Canada
5Department of Human Genetics, McGill University, Montréal, QC, Canada
MD, PhDAlastair J Noyce
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
6Department of Clinical & Movement Neurosciences, UCL Institute of Neurology, London, UK
PhDData Availability
All data is available from the studies used.
Posted November 13, 2020.
Type 2 diabetes as a determinant of Parkinson’s disease risk and progression
Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce
medRxiv 2020.11.12.20230474; doi: https://doi.org/10.1101/2020.11.12.20230474
Subject Area
Subject Areas
- Addiction Medicine (367)
- Allergy and Immunology (688)
- Anesthesia (184)
- Cardiovascular Medicine (2740)
- Dermatology (234)
- Emergency Medicine (412)
- Epidemiology (12388)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4252)
- Geriatric Medicine (394)
- Health Economics (699)
- Health Informatics (2749)
- Health Policy (1017)
- Hematology (369)
- HIV/AIDS (878)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (451)
- Neurology (4027)
- Nursing (216)
- Nutrition (598)
- Oncology (2122)
- Ophthalmology (604)
- Orthopedics (251)
- Otolaryngology (311)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1146)
- Primary Care Research (465)
- Public and Global Health (6646)
- Radiology and Imaging (1444)
- Respiratory Medicine (886)
- Rheumatology (420)
- Sports Medicine (351)
- Surgery (464)
- Toxicology (57)
- Transplantation (192)
- Urology (171)